Investment Rating - The report maintains a "Buy" rating for the company, anticipating a price increase of over 15% in the next 6-12 months [6]. Core Insights - The company reported a revenue of approximately 2.186 billion RMB for 2025, representing a year-on-year growth of 6.1%. The net profit attributable to shareholders was about 558 million RMB, up 30.2% year-on-year, with a net profit margin of 25.5%, an increase of 4.7 percentage points [3]. - The product structure continues to optimize, with high-value-added businesses growing steadily. Revenue from standardized lenses reached 1.021 billion RMB (+12.6%), while functional lenses generated 768 million RMB (+1.7%). Customized lenses saw a slight decline to 393 million RMB (-0.6%) due to U.S. tariff impacts [4]. - The company's XR business is expected to become a core growth engine, with successful progress in smart glasses and partnerships with industry leaders, indicating significant revenue and profit contributions starting in 2026 [5]. Financial Performance - The company forecasts net profits of 695 million RMB, 840 million RMB, and 1.049 billion RMB for 2026, 2027, and 2028, respectively, reflecting growth rates of 24.61%, 20.84%, and 24.96% [6]. - The gross profit margin for 2025 was 42.0%, an increase of 3.4 percentage points, driven by product mix upgrades and higher contributions from high-margin proprietary brands [4]. - The company plans to expand its production capacity in Japan and initiate operations at its Thailand facility, accelerating its global capacity layout [4].

Investment Rating - The report maintains a "Buy" rating for Xiaomi Group [3][5] Core Views - Xiaomi Group's revenue for 2025 reached 457.3 billion yuan, a year-on-year increase of 25%, while adjusted net profit was approximately 39.2 billion yuan, up 43.8% year-on-year [1] - The company aims to deliver 550,000 cars in 2026, with a significant increase in automotive deliveries expected [2] - Xiaomi's AI capabilities are gaining traction, with new models and applications expected to enhance its ecosystem [2] Financial Summary - Revenue projections for Xiaomi Group are as follows: 509.6 billion yuan in 2026, 576.0 billion yuan in 2027, and 623.4 billion yuan in 2028, with adjusted net profits of approximately 34.5 billion yuan, 42.8 billion yuan, and 50.3 billion yuan respectively [4][11] - The company is expected to face a decline in smartphone gross margin to around 8% in 2026 due to rising storage costs [1] - The adjusted net profit margin is projected to be 6.8% in 2026, with a year-on-year decrease of 12% [11]

Investment Rating - The report maintains a "BUY" rating for 3SBio, indicating a potential return of over 15% over the next 12 months [6][15]. Core Insights - 3SBio reported a revenue of RMB 17.7 billion in 2025, a significant increase of 94.3% year-over-year, primarily driven by RMB 9.4 billion in out-licensing income from Pfizer for product 707. However, product sales experienced a decline of 10.3% year-over-year to RMB 8.0 billion due to challenges from China's VBP and reimbursement controls [1][2]. - The company is expected to maintain high R&D investments to accelerate pipeline progress, with a focus on product 707, which is seen as the primary valuation anchor due to Pfizer's aggressive global development strategy [1][6]. - The report anticipates that while commercialized products, especially TPIAO, may face continued pressure in 2026, new product approvals and pipeline candidates could help offset declines in traditional product sales [6][8]. Financial Summary - Revenue projections for 2026 are revised down to RMB 9.17 billion, reflecting a 48.2% decline from 2025, with a net profit forecast of RMB 1.90 billion, down 77.6% year-over-year [2][7]. - The report highlights a significant increase in R&D and administrative expense ratios, which rose approximately 4 percentage points and 2 percentage points, respectively, due to accelerated clinical investments and one-off share-based compensation [1][6]. - The target price for 3SBio has been adjusted to HK$ 34.87 from a previous HK$ 37.43, representing a 54% upside from the current price of HK$ 22.64 [3][6]. Pipeline and Product Development - 3SBio has developed a broad pipeline of 27 candidates, with several already obtaining US FDA INDs, including SSS67 and SSS68, which target various medical conditions and demonstrate the company's global R&D strategy [6][8]. - Near-term catalysts include updated Phase 2 data for NSCLC and EC at ASCO 2026, which are expected to drive milestone payments and enhance earnings [6][8]. - Recent product approvals, such as NuPIAO and SSS20, along with NRDL inclusion for oral paclitaxel, are anticipated to generate revenue in 2026 and partially offset declines from traditional products [6][8].

Investment Rating - Maintain BUY rating for Yongda Automobiles, indicating potential for significant returns despite current challenges [1][8] Core Views - The report suggests that further deterioration in new-car gross profit margins (GPM) is limited due to luxury OEMs lowering manufacturer suggested retail prices (MSRPs) and exploring agency models [1] - The auto dealer industry is in a "survival of the fittest" phase, with established leaders like Yongda expected to be long-term survivors [1] - Yongda's expertise in new energy vehicle (NEV) dealership is viewed as a key competitive advantage as most brands will continue to rely on dealers [1] Financial Summary - Revenue projections show a decline from RMB 74,296 million in FY23A to RMB 54,600 million in FY25E, with a YoY growth of -14.6% in FY24A and -13.9% in FY25E [2][12] - Net profit is expected to drop significantly, from RMB 572.6 million in FY23A to a loss of RMB 5,071.5 million in FY25E, with a recovery projected in FY26E to RMB 38 million [2][12] - Earnings per share (EPS) is forecasted to decrease from RMB 0.29 in FY23A to a loss of RMB 2.72 in FY25E, with a slight recovery to RMB 0.02 in FY26E [2][12] Target Price and Valuation - The target price for Yongda has been revised down from HK$2.50 to HK$1.80, reflecting a 29.5% upside from the current price of HK$1.39 [3] - The valuation is based on a 10x FY27E P/E, indicating increased sensitivity to new-car GPM recovery [8] Earnings and Margin Projections - New-car GPM is projected to recover from 0.1% in FY25 to 0.3% in FY26E, driven by increased transaction prices and OEMs' MSRP cuts [8] - The report anticipates stable operating expenses despite potential revenue declines due to planned store closures [8] Share Performance - The stock has experienced a decline of 27.2% over the past six months, indicating market challenges [5]

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [2][5]. Core Insights - The company, Lin Qingxuan, is positioned as the leading brand in the high-end facial oil segment, with a market share of 12.4% in 2024, reflecting its strong brand resilience and adaptability through various market challenges [4][20][24]. - The company has demonstrated significant growth, with a projected revenue increase from 2.45 billion RMB in 2025 to 5.50 billion RMB by 2028, indicating a compound annual growth rate (CAGR) of 36.01% [6][5]. - Lin Qingxuan's innovative product strategy, particularly the successful launch of the "Little Gold Pearl Water," showcases its ability to expand its product categories while maintaining a strong brand identity [5][55]. Summary by Sections 1. Company Overview - Lin Qingxuan has evolved into a top brand in the facial oil market since its establishment in 2003, transitioning from wholesale to a fully integrated online and offline retail model [16][24]. - The brand has successfully navigated multiple crises, demonstrating strategic agility and a commitment to high-end positioning [24][30]. 2. Product Differentiation - The company has focused on the Camellia oil product line, which has undergone five iterations since its launch in 2014, solidifying its market position [39][44]. - In 2025, the revenue from essential oil products reached 1.02 billion RMB, accounting for 42% of total revenue, with a year-on-year growth of 128.7% [44][5]. 3. Sales Channels - Lin Qingxuan's online sales have surged, with a 70% contribution to total revenue in 2025, driven by platforms like Douyin [5][12]. - The company has expanded its offline presence, increasing the number of stores to 580 by the end of 2025, with a same-store sales growth of 19.6% in the first half of 2025 [5][12]. 4. Organizational Efficiency - The establishment of a matrix organizational structure has enhanced decision-making efficiency and product development capabilities, allowing for rapid innovation and market responsiveness [5][4]. - The successful launch of new products, such as the "Little Gold Pearl Water," reflects the effectiveness of this organizational model [5][55]. 5. Financial Projections - The company is expected to achieve net profits of 573 million RMB in 2026, 774 million RMB in 2027, and 1 billion RMB in 2028, with respective growth rates of 59.1%, 35.0%, and 29.2% [6][5]. - The projected price-to-earnings (P/E) ratios for 2026, 2027, and 2028 are 14, 11, and 8 times, respectively, indicating a favorable valuation outlook [5][6].

Investment Rating - The report assigns a "Buy" rating for the company, with a target price of HKD 48.24, based on a DCF valuation method [8][10]. Core Insights - The company focuses on the development of innovative drugs in the metabolic and oncology fields, with promising pipelines such as LAE102 and LAE002, which are expected to address significant market needs and have strong potential for business development [8][10]. - LAE102, targeting the ActRII pathway, shows superior muscle gain and fat loss potential compared to existing GLP-1 drugs, addressing the muscle loss issue associated with weight loss treatments [8][10]. - LAE002 is positioned as a leading AKT inhibitor, addressing drug resistance in advanced breast cancer, with a successful licensing agreement with Qilu Pharmaceutical, validating its pipeline value [8][10]. Summary by Sections 1. Company Overview - The company, established in 2016, focuses on developing therapies for metabolic diseases, cancer, and liver fibrosis, with a robust pipeline including LAE102, LAE103, and LAE002 [13][21]. 2. Metabolic Pipeline - The ActRII pipeline demonstrates differentiated mechanisms with superior safety and muscle gain effects, potentially becoming a cornerstone therapy in weight loss when combined with GLP-1 drugs [8][10]. - Clinical data shows LAE102's effectiveness in fat reduction and muscle preservation, outperforming other small nucleic acid drugs in terms of muscle gain [8][10]. 3. Oncology Pipeline - LAE002 effectively blocks the PI3K/AKT/mTOR signaling pathway, addressing drug resistance in HR+/HER2- breast cancer, and has secured a licensing deal with Qilu Pharmaceutical, enhancing its commercial prospects [8][10]. - The company is advancing LAE002 through multiple clinical trials, with promising results in terms of efficacy and safety compared to existing treatments [8][10]. 4. Financial Projections - Revenue projections for the company are estimated at HKD 730 million in 2026, with a significant increase in net profit expected in the same year [8][10].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The report highlights that the company, Meitu, is expected to leverage AI technology to enhance its competitive edge in the aesthetic economy, with significant growth in revenue and profitability anticipated in the coming years [8] - The company's revenue for 2025 is projected to be 3.859 billion yuan, with a year-on-year growth rate of 15.5%, and a net profit of 583 million yuan, reflecting a decline of 27.6% due to a high base effect from previous one-time gains [10] - The report emphasizes the importance of AI in driving user engagement and subscription growth, particularly through the introduction of AI-powered features and tools [6][7] Summary by Sections Financial Performance - In 2025, the company's revenue is expected to reach 3.859 billion yuan, with a growth rate of 15.5% [10] - The net profit for 2025 is forecasted at 583 million yuan, with a significant rebound expected in subsequent years, projecting net profits of 1.217 billion yuan in 2026 and 1.504 billion yuan in 2027 [10] - The earnings per share (EPS) is projected to increase from 0.13 yuan in 2025 to 0.40 yuan by 2028 [10] Business Strategy - The company is focusing on enhancing its global strategy, with a notable increase in paid subscription users outside of China, particularly in the US and Europe [5] - The introduction of AI features is expected to drive user growth, with the monthly active users projected to reach 276 million by 2025, a year-on-year increase of 3.8% [4][5] - The report indicates that the AI capabilities will not only reduce costs but also elevate the quality of product offerings, making aesthetic competence a new competitive advantage [6] Market Outlook - The company is expected to see its revenue grow significantly, with forecasts of 4.957 billion yuan in 2026 and 5.946 billion yuan in 2027, reflecting a strong upward trend in the aesthetic economy driven by AI [8][10] - The report suggests that the AI-driven aesthetic economy will become a key competitive factor, as companies must understand customer needs deeply to deliver satisfactory products [6]

Investment Rating - The investment rating for Xiaocaiyuan International has been downgraded to "Neutral" [2][3]. Core Insights - Xiaocaiyuan is expected to achieve revenue growth in 2025, with a forecast of RMB5,707 million, RMB6,970 million, and RMB7,852 million for 2026-2028, representing year-on-year growth rates of +6.8%, +22.1%, and +12.7% respectively. Net profit is projected at RMB634 million, RMB783 million, and RMB898 million, with corresponding growth rates of -11.3%, +23.4%, and +14.7% [3][13]. - The company is entering a strategic adjustment year in 2026, focusing on proactive price reductions for dine-in services to enhance its "value-for-money" positioning, which is expected to lead to a decrease in gross margin from 70.4% in 2025 to 65.0% [5][15]. - The 88VIP membership program has shown strong initial performance, adding over 410,000 members within two and a half months and achieving a repurchase rate exceeding 40%, which is expected to drive customer traffic during the adjustment year [6][16]. Financial Performance Summary - In 2025, Xiaocaiyuan reported a revenue of RMB5,345.1 million, a year-on-year increase of 2.6%. The net profit reached RMB715.1 million, reflecting a growth of 23.2% year-on-year, with a net profit margin of 13.4% [4][14]. - The company added a net of 146 stores in 2025, bringing the total to 819, with 807 under the Xiaocaiyuan brand. Stores in tier-3 and below cities accounted for 42.5% of the total [4][14]. Strategic Initiatives - The company is implementing a "premium delivery" strategy, capping delivery mix at 30% during peak hours, and has reduced prices on signature dishes to maintain customer engagement [5][15]. - Supply chain enhancements include the establishment of 16 forward warehouses for efficient ingredient delivery and the upcoming launch of a smart factory in Ma'anshan, expected to support cost control during the adjustment year [8][17]. - The new store model has demonstrated high efficiency, with a breakeven period of approximately one month and a payback period of about 12 months, indicating strong replicability [8][18].

Investment Rating - The investment rating for Mixue Group has been downgraded to "Neutral" with a target price of HK$267.30, indicating a potential downside of 6.6% from the current price of HK$293.00 [2][4]. Core Insights - The report highlights that in 2026, the withdrawal of domestic subsidy policies and the shift in consumer purchasing habits towards online channels will increase the demands on the company's online operational capabilities. The company plans to adhere to a "quality-first" strategy and will slow down the pace of new store openings while focusing on existing store operations [4][13]. - Revenue projections for Mixue Group are estimated to reach RMB 37.28 billion, RMB 42.61 billion, and RMB 48.85 billion from 2026 to 2028, reflecting year-on-year growth rates of 11.1%, 14.3%, and 14.6% respectively. Net profit attributable to the parent company is expected to be RMB 6.19 billion, RMB 7.26 billion, and RMB 8.58 billion during the same period, with corresponding growth rates of 5.1%, 17.2%, and 18.3% [4][13]. - The company is facing operational challenges due to a significant shift in consumer behavior towards online shopping, which has impacted its traditional in-store sales model. The management anticipates pressures on store turnover and profitability in 2026 and is implementing measures to drive revenue and profit growth [5][14]. Financial Summary - For the fiscal year 2025, Mixue Group reported total revenue of RMB 33.56 billion, a year-on-year increase of 35.2%, and a net profit of RMB 5.93 billion, up 33.1% year-on-year. The operating profit margin was recorded at 17.1%, a slight decrease from the previous year [8][16]. - The company’s projected earnings per share (EPS) for 2026, 2027, and 2028 are RMB 16.38, RMB 19.18, and RMB 22.67 respectively, with price-to-earnings (P/E) ratios of 15.5X, 13.2X, and 11.2X for the same years [4][13].

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Insights - The company reported a revenue of USD 1.66 billion for 2025, reflecting a year-on-year increase of 4.14%. However, the net profit was a loss of USD 0.19 billion, compared to a profit of USD 0.09 billion in the previous year. The adjusted net profit was USD 0.31 billion, showing a significant increase of 338.0% year-on-year [10] - The revenue growth is attributed to the stable performance of Joyoung and the continued high growth of SharkNinja in the Asia-Pacific region. The company expects net profits for 2026-2028 to be USD 0.63 billion, USD 0.86 billion, and USD 1.00 billion respectively, with EPS projected at USD 0.02, USD 0.02, and USD 0.03 [10] - The report highlights that the revenue from Joyoung and SharkNinja's third-party customers was USD 1.03 billion and USD 0.53 billion respectively, with year-on-year growth of 1.1% and 55.6%. The overall revenue contribution from these segments was 62.2% and 32.1% of total revenue [10] Financial Summary - The total revenue for 2024A was USD 1.43 billion, with projections for 2025A at USD 1.66 billion, 2026E at USD 1.84 billion, 2027E at USD 2.09 billion, and 2028E at USD 2.31 billion. The net profit for 2025A is projected at a loss of USD 0.24 billion, with a recovery expected in subsequent years [5] - The gross margin for 2025 was 32.17%, a slight increase of 0.15 percentage points year-on-year. However, the gross margin for third-party sales decreased to 33.5%, down 0.5 percentage points [10] - The sales expense ratio for 2025 was 21.4%, an increase of 0.6 percentage points, primarily due to increased advertising and marketing investments by SharkNinja [10]